

March 2006 Extraordinary Meeting PBAC Outcomes – Positive Recommendations

Drug and Form	Drug Use and Type	Listing Requested by Sponsor	PBAC Recommendation
<p>Insulin glargine, injection, 100 units per mL, 10 mL vials and 3 mL x 5 cartridges, Lantus®</p> <p>Sanofi-Aventis Group</p> <p>Major submission</p>	<p>Treatment for diabetes</p>	<p>Unrestricted listing</p>	<p>The PBAC recommended the listing of insulin glargine as an unrestricted benefit on the basis that the clinical benefit over NPH insulin (improvement in hypoglycaemic event rates) in a population which cannot be defined effectively, but which is likely to include those with a high level of need, was cost-effective at the new price proposed.</p>
		<p><i>Sponsor's comments</i></p>	<p>Sanofi-aventis is pleased that we have been able to reach agreement with the PBAC. The efforts of both PBAC and sanofi-aventis have been in good faith and we look forward to the positive recommendation of the PBAC being accepted by the Government in the near future.</p>